Drug
INOmax
INOmax is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Terminated1
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (100.0%)
Trials by Status
terminated133%
completed133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation
NCT03455218
terminated
Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension
NCT03132428
unknown
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
NCT03972566
Clinical Trials (3)
Showing 3 of 3 trials
NCT03455218Phase 2
Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation
NCT03132428
Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension
NCT03972566
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3